Kevin Tang has done it again.
Just a few days ago we wrote an article on Penwest Pharma (PPCO) and the possibility of realizing over-average returns in the near term due to Kevin Tang’s push to wind down the company’s operations so that shareholders could fully realize the OpanaER royalty payments. If that was the case, shareholders would have been able to realize roughly $23 mm of annual royalty payments until at least 2013, which represented a 21% annual return on investment over those three years based on the enterprise value of $111mm at the time the previous article was written.
Monday, Endo Pharmaceutical (OTCPK:ENDO) said it agreed to buy Penwest Pharmaceuticals for about $168 million in cash, to broaden its pain drug portfolio. Endo said it expects the deal at $5 a share, a premium of 32% percent to Penwest’s price at the time the initial article was written. The purchase translates into a 14% return on investment for Endo for the next 3 years, with the opportunity to further develop and expand OpanaER into foreign markets (OpanaER has only been approved in the US).
Endo also said it filed a new drug application with the U.S. Food and Drug Administration for a new extended-release formulation of oxymorphone to treat moderate to severe pain in patients requiring continuous opioid treatment. Penwest shareholders Tang Capital Partners and Perceptive Advisors, and Chief Executive Jennifer Good, who collectively own 38.6 percent of Penwest common stock, have committed to tender their shares in the offer, Endo said in a statement.
Out of all the investors we currently follow, Kevin Tang has been by far one of the most skillful at spotting investment opportunities as well as adapting to the conditions of the equity markets. In March 2009, when everyone was fearful to invest, Mr. Tang took a position in Vanda (VNDA), which paid off handsomely soon after. There is no doubt that we will continue to study Mr. Tang’s approach to investing and spotting investment opportunities.
Disclosure: No Positions